血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化*

doi:10.3969/j.issn.1672-5069.2020.06.011

摘要/Abstract

摘要： 目的调查血清HBeAg阴性的慢性乙型肝炎(CHB)患者天门冬氨酸氨基转移酶与血小板比值(APRI)、基于4因子指数(FIB-4)和血清转化生长因子-β1(TGF-β1)的变化。方法 2018年1月～2019年5月我院诊治的血清HBeAg阴性的CHB患者78例和同期健康人78例,采用ELISA法测定血清TGF-β1水平,常规检测血生化指标,计算APRI和FIB-4评分。CHB患者接受肝活检,并行肝纤维化分期。结果 CHB患者APRI评分为(0.9±0.4),显著高于健康人【(0.3±0.1),P<0.05】;FIB-4评分为(1.4±0.4),显著高于健康人【(0.5±0.2),P<0.05】,血清TGF-β1水平为(14.5±5.3)ng/ml,显著高于健康人【(7.4±3.5)ng/ml,P<0.05】;33例CHB患者肝组织F0～1者APRI评分为(0.5±0.2),显著低于24例肝组织F2者【(1.0±0.3),P<0.05】,显著低于12例肝组织F3者【(1.3±0.5),P<0.05】,也显著低于9例肝组织F4者【(1.8±1.6),P<0.05】;F0～1患者FIB-4评分为(0.9±0.3),显著低于F2患者【(1.5±0.4),P<0.05】,显著低于F3患者【(1.9±0.4),P<0.05】,也显著低于F4患者【(3.2±0.6),P<0.05】;F0～1患者血清TGF-β1水平为(9.7±3.6)ng/ml,显著低于F2患者【(10.5±4.4)ng/ml,P<0.05】,显著低于F3患者【(15.8±5.9)ng/ml,P<0.05】,也显著低于F4患者【(19.5±6.2)ng/ml,P<0.05】。结论血清HBeAg阴性的CHB患者APRI、FIB-4和血清TGF-β1水平发生了显著的变化,随着肝纤维化程度的加重,这些指标变化更明显,可能有助于提高对肝纤维化的诊断。

关键词: 慢性乙型肝炎, 肝纤维化, 天门冬氨酸氨基转移酶/血小板计数比值, 基于4因子指数, 转化生长因子-β1

Abstract: Objective The aim of this study was to investigate the changes of ratio of aspartate aminotransferase to platelet counts (APRI), based on fibrosis-four (FIB-4) and serum transforming growth factor-β1 (TGF-β1) in patients with serum HBeAg negative chronic hepatitis B (CHB). Methods 78 patients with serum HBeAg-negative CHB and 78 healthy persons were enrolled in our hospital from January 2018 through May 2019, and the APRI, FIB-4 and serum TGF-β1 levels were detected or calculated. The liver biopsies were performed in all patients with CHB. Results The APRI score in patients with CHB was (0.9±0.4), which was significantly higher than that in the healthy group [(0.3±0.1), P<0.05] , the FIB-4 score was (1.4±0.4), significantly higher than [(0.5±0.2), P <0.05] in the healthy persons, and serum TGF-β1 level in patients with CHB was (14.5±5.3) ng / ml, which was significantly higher than [(7.4±3.5), P< 0.05] ng / ml in healthy persons; the APRI score in 33 patients with hepatic F0-1 fibrosis was (0.5±0.2), significantly lower than [(1.0±0.3),P<0.05] in 24 patients with F2, significantly lower than [1.3.±0.5), P<0.05】 in 12 patients with F3, and also significantly lower than [(1.8±1.6), P <0.05] in 9 patients with F4; the FIB-4 score in patients with F0-1 was (0.9±0.3), significantly lower than [(1.5±0.4), P < 0.05] in patients with F2, significantly lower than [(1.9±0.4), P <0.05] in patients with F3, and also significantly lower than [(3.2±0.6), P <0.05] in patients with F4; the serum TGF-β1 level in patients with F0-1 was (9.7±3.6) ng / ml, which was significantly lower [(10.5±4.4) ng / ml, P<0.05] in patients with F2, significantly lower than [(15.8±5.9) ng / ml, P<0.05] in patients with F3, and also significantly lower than [(19.5±6.2) ng / ml, P<0.05] in patients with F4. Conclusion The APRI and FIB-4 scores as well as serum TGF-β1 levels in serum HBeAg-negative patients with CHB increase greatly, which might help improve the diagnostic accuracy of liver fibrosis in this setting.

Key words: Chronic hepatitis B, Liver fibrosis, Ratio of aspartate aminotransferase to platelet count, Transforming growth factor-β1

唐平阳, 王洁冰, 张晓兰, 唐启群. 血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 801-804.

Tang Pingyang, Wang Jiebing, Zhang Xiaolan, et al. Changes of APRI and FIB-4 scores in patients with serum HBeAg-negative chronic hepatitis B[J]. Journal of Practical Hepatology, 2020, 23(6): 801-804.

参考文献

[1] Barroeta A B, Simonetti S, Vitale S, et al. GM - CSF inhibits c -kit and scf expression by bone marrow-derived dendritic cells. Front Immunol, 2017, 8(1): 146-147.
[2] Parikh P, Ryan J D, Tsochatzis E A, et al. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection . Ann Transl Med, 2017, 5(3): 40 -53.
[3] Xu Y, Tang X P, Zhang Y H, et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology, 2015, 62(6): 1731–1741.
[4] 程渝, 郭锐, 刘明国, 等. MRI与血清学定量指标检测对肝纤维化的诊断价值. 中华实用诊断与治疗杂志, 2018, 32(6):589-593.
[5] 闫蓉, 高保华, 田秋梅, 等. RPR FIB-4 APRI及AAR对107例慢性乙型肝炎肝纤维化的诊断准确性比较. 中国实用内科杂志, 2019, 39(3):249-253.
[6] 刘红, 吴疆. 国内外慢性乙型肝炎防治指南比较:抗病毒治疗诊断标准和治疗方案. 中国肝脏病杂志(电子版), 2018, 10(1):10-17.
[7] Luo H, Zhang X X, Cao L H, et al. Serum hepatitis b virus rna is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis b patients. World J Gastroenterol, 2019, 25(6): 719–728.
[8] Joshua D R, Ryan E, Robert H M, et al. Hepacivirus a infection in horses defines distinct envelope hypervariable regions and elucidates potential roles of viral strain and adaptive immune status in determining envelope diversity and infection outcome. J Virol, 2018 , 92(18): 14-18.
[9] Motta M, Sejal M, Márcio T N, et al. A novel hepacivirus in wild rodents from south america. Viruses, 2019 ,11(3): 296-297.
[10] 李军, 陈攀, 陈孝, 等. 以DJ-1蛋白为靶点治疗肝纤维化的研究进展. 中国药理学通报, 2018, 34(3):309-312.
[11] Yan J, Kim E M, Choi M H, et al. Significance of serology by multi-antigen elisa for tissue helminthiases in Korea. J Korean Med Sci, 2017,32(7): 1118–1123.
[12] Liao R, Fu Y P, Wang T, et al. Metavir and fib-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget, 2017 , 8(1): 1774–1787.
[13] Sarin S K, Kumar M, Lau G K, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016 ,10(1): 1–98.
[14] Tong M J, Pan C Q, Han S H, et al. An expert consensus for the management of chronic hepatitis b in Asian Americans. Aliment Pharmacol Ther,2018 ,47(8): 1181–1200.
[15] Elia M C, Robert T S, Julia P A, et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis b patients. World J Gastroenterol, 2018, 24(17): 1825–1838.
[16] 金彩婷,郭利伟,梁伟峰. 慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展. 中华实验和临床感染病杂志(电子版), 2018, 12(1):11-14.
[17] Zhang G L, Zhao Q Y, Lin C S, et al. Transient elastography and ultrasonography: optimal evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease. Biomed Res Int, 2019, 20(1): 3951-3957.
[18] Yan L T, Wang L L, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis b virus infection. Medicine (Baltimore), 2020, 99(8): 19248-19249.
[19] Xu S H, Li Q , Hu Y P, et al. Development of a model based on biochemical, real-time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B. Mol Med Rep, 2016, 14(4): 3609-3619.
[20] Mak L Y, Danny K H, Cheung K S, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol, 2018, 9(6): 163-164.
[21] Sadhna D, Stephen C W, Swan N T, et al. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol, 2016, 22(4): 1357–1366.
[22] Maria P S, Barbara K M, Małgorzata A, et al. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infect Dis, 2017, 17(1): 355-361.
[23] Wu N, Meng F y, Zhou T H, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-β1–mediated biliary senescence. Am J Pathol, 2018, 188(10): 2264–2280.
[24] Liu N, Feng J, Lu X Y, et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the tgf-β1/smad3 and tgf-β1/p38 mapk pathways. Mediators Inflamm, 2019, 20(1): 617-619.
[25] Min H J, Ka Y H, Ji H P, et al. New mechanism of hepatic fibrogenesis: hepatitis c virus infection induces transforminggrowth factor β1 production through glucose-regulated protein 94. J Virol, 2016, 90(6): 3044–3055.

血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化^*

Changes of APRI and FIB-4 scores in patients with serum HBeAg-negative chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[2]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[3]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[4]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[5]	宋金云, 王建芳, 赵宏宇. 慢性乙型肝炎和肝硬化患者血清HBV基因型分析[J]. 实用肝脏病杂志, 2021, 24(1): 87-90.
[6]	刘瑞清(综述), 袁小澎(审校). 缺氧诱导因子-1α参与肝纤维化形成机制研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 145-148.
[7]	宋叶雨(综述), 范建高(审校). 少肌性肥胖合并脂肪性肝病的诊断与治疗[J]. 实用肝脏病杂志, 2021, 24(1): 149-152.
[8]	韩冬, 陆洋, 柏根基, 史昭菲. 超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 789-792.
[9]	詹爱琴, 陈春丽, 朱庆峰, 李冰洁, 左维泽, 卢丽君. 异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 793-796.
[10]	柳迪, 董鑫, 杨建军, 吴云英, 张龙方, 刘妍. 瞬时弹性成像联合门静脉血流动力学指标诊断慢性乙型肝炎患者肝纤维化意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(6): 797-800.
[11]	崔璐瑶, 苑喜微, 刘领弟, 张莹, 赵文, 赵丹丹, 杨杨, 南月敏. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 809-812.
[12]	方奕, 陈毅雄, 裴冬萍, 操银针. 恩替卡韦联合复方嗜酸乳杆菌治疗CHB合并NAFLD患者疗效及其对血清相关酶系的影响[J]. 实用肝脏病杂志, 2020, 23(5): 634-637.
[13]	吴雄飞, 方利娟, 陈艳. 替诺福韦联合干扰素-α治疗HBeAg阳性慢性乙型肝炎患者疗效及其血清细胞因子水平变化[J]. 实用肝脏病杂志, 2020, 23(5): 638-641.
[14]	张浩, 常建东, 陈小燕. 超声弹性成像结合血清学指标诊断慢性乙型肝炎患者肝纤维化价值评价[J]. 实用肝脏病杂志, 2020, 23(5): 642-645.
[15]	周莹, 陈娇, 叶龙, 刘启榆, 钟唐力. CT测量肝外基质体积分数评估慢性乙型肝炎患者肝纤维化临床应用研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 492-495.